Driving our vision to success
Jack A. Khattar
PRESIDENT AND CHIEF EXECUTIVE OFFICER, DIRECTOR
Jack A. Khattar is the founder of our company and has served as our President, Chief Executive Officer (CEO), Secretary and a Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions as a Board member, President and CEO of Shire Laboratories, Inc., the drug delivery subsidiary ... of Shire plc. From 1999 to 2004, he also served as a member of Shire plc’s Executive Committee. Prior to that, Khattar served as an Executive Officer and the Chairman of the Management Committee at CIMA Labs Inc., a drug delivery company, where he was also responsible for business development, corporate alliances, and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex, and Kodak in various locations, including the United States, Europe, and the Middle East. Mr. Khattar served on the Board of Rockville Economic Development Inc. from 2003 until 2013. He currently serves on the Board of Directors of Prevacus, Inc., a privately held development stage biotechnology company, and is also Chairman of the Board of scPharmaceuticals, a publicly traded biotechnology company. Mr. Khattar earned his degrees in marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania. ...Read More +
Kevin T. Anderson, Esq.
Kevin T. Anderson, Esq, has served as Compliance Officer since 2012. Mr. Anderson previously held positions as Compliance Officer and Vice President of Human Resources at Xanodyne Pharmaceuticals, General Counsel for U.S. Commercial Operations at Shire Pharmaceuticals, and ...as a manager with the Emerging Business Group at Ernst & Young.
Mr. Anderson earned his BSBA with majors in Accounting and Finance from Ohio Northern University and a Juris Doctorate degree from the University of Cincinnati College of Law. ...Read More +
Padmanabh P. Bhatt, Ph.D
SENIOR VICE PRESIDENT
CHIEF SCIENTIFIC OFFICER
Padmanabh P. Bhatt, Ph.D, has served as our Senior Vice President of Intellectual Property and Chief Scientific Officer since March 2012. Prior to that, he served as our Vice President of Pharmaceutical Sciences beginning in 2005. From 2003 to 2005, Dr. Bhatt was Vice President of Advanced Drug ... Delivery at Shire Laboratories, Inc. From 2001 to 2003, Dr. Bhatt served as Vice President of Research and Development and Chief Technology Officer at Point Biomedical Corporation. From 1996 to 2001, he served at ALZA (now a Johnson & Johnson company) in various positions, from Product Development Manager to Director of Technical Development. Prior to that time, Dr. Bhatt held positions as Research Specialist and Group Leader of Novel Drug Delivery at Dow Corning Corporation (from 1992 to 1996) and Senior Scientist at Hercon Laboratories (from 1989 to 1992).
Dr. Bhatt earned his B.Pharm and M.Pharm degrees from the University of Bombay, India. He also holds M.S. and Ph.D. degrees in Pharmaceutical Chemistry from the University of Kansas. ...Read More +
Jeff Bozick has served as our Vice President of Supply Chain since December 2013. Prior to that, he served as our Executive Director of Supply Chain upon joining in November 2011. Mr. Bozick has over 30 years of experience in Life Science Supply Chain Management. From 2006 to 2011, he was ...Director of Outsourced Supply Operations at Eisai Inc. From 2004 to 2006, Mr. Bozick was the Director of Supply Operations at Ligand Pharmaceuticals until its Oncology division was acquired by Eisai. From 1997 to 2004, he served as Director of Manufacturing and Materials at Alliance Pharmaceutical Corp. Prior to joining Alliance, Mr. Bozick held various supply chain and consulting positions at Hybritech Inc., Beckman Instruments, and La Jolla Pharmaceuticals. ...Read More +
Todd Horich Ph.D, MBA
Todd Horich, Ph.D, MBA, has served as our Vice President of Marking since January 2015. Since joining Supernus as the first commercial employee in 2010, Dr. Horich has played an integral leadership role in the successful launch of Trokendi XR® and Oxtellar XR®, and build out of the organization. From ... 2010 to 2014, he was responsible for building and leading the Marketing Team, as well as responsible for New Product Planning and Commercial Development. Prior to joining Supernus, Dr. Horich held various positions of increasing responsibility with Novartis Pharmaceuticals Inc., as well as Director level positions with Vanda Pharmaceuticals and Medimmune, Inc.
Dr. Horich earned his Ph.D in Pharmaceutical Sciences from the University of Maryland, and a Master of Business Administration from the University of Baltimore. He also holds an MS and a BS in Biological Sciences from the University of Maryland. He has received numerous awards and accolades throughout his career, and was recognized in 2017 by Pharmaceutical Executive Magazine as an Emerging Pharmaceutical Leader. ...Read More +
EXECUTIVE VICE PRESIDENT
CHIEF FINANCIAL OFFICER
James Kelly has served as our Executive Vice President, Chief Financial Officer since October 2020. Previously, Mr. Kelly was Executive Vice President, Chief Financial Officer of Vanda Pharmaceuticals, a public biopharmaceutical company, where he served as Chief Financial Officer from 2010 ... to 2020. Mr. Kelly held finance roles at Medimmune, a biotechnology subsidiary of AstraZeneca Group, from 2006 to 2010, most recently as Vice President, Controller. From 2000 to 2005, Mr. Kelly was at Biogen serving in research and development finance roles of increasing responsibility, most recently as Director of Planning and Operations. From 1997 to 2000, Mr. Kelly was a member of the corporate finance team at Aetna Inc., responsible for mergers and acquisitions and treasure management. He began his life sciences career in 1991 with Janssen Pharmaceuticals, a division of Johnson & Johnson. Mr. Kelly is a CFA charterholder and a member of the Associate of Bioscience Financial Officers. He received his Bachelor of Science in Business Administration from the University of Vermont and his Master of Business Administration from Cornell University. ...Read More +
Tami T Martin, RN, Esq.
SENIOR VICE PRESIDENT
Tami T. Martin, RN, Esq, has served as Senior Vice President of Regulatory Affairs since 2008. Ms. Martin previously held positions as Vice President of Regulatory Affairs at Shire Pharmaceuticals and Manager to Senior Director of Regulatory Affairs at Otsuka America Pharmaceutical, Inc. Ms. Martin also ... consulted privately for domestic and international clients as President and CEO of Pyramid Regulatory Consulting.
Earlier in her career, Ms. Martin held legal positions at Hogan & Hartson as a member of the Food and Drug Practice Group, and with the Department of Health and Human Services as staff attorney.
Ms. Martin has served as an instructor for the Johns Hopkins University Master of Biotechnology and Regulatory Affairs Graduate Degree program, and, for years, taught a portion of the United States Regulatory Module for TOPRA (The Organisation for Professionals in Regulatory Affairs). ...Read More +
SENIOR VICE PRESIDENT
QUALITY, GMP OPERATIONS, AND INFORMATION TECHNOLOGY
Frank Mottola was promoted to Senior Vice President of Quality, GMP Operations and Information Technology in 2020. Previously, he served as Vice President of Quality, GMP Operations and Information Technology beginning in 2017. From 2014-2017, he served as Vice President of Quality ... and GMP Operations. Initially he joined Supernus as Director of Quality in 2005, responsible for initiating Quality Systems at the company’s inception. Prior to that time, Mr. Mottola was the Director of Quality at Able Laboratories and previously held positions at Ortho Clinical Diagnostics (Johnson & Johnson). He has 24 years of experience in the pharmaceutical industry and holds a Bachelor’s degree in Biology and Business Administration while attending Rutgers University and Walden University. ...Read More +
SALES & MARKET ACCESS
Taylor Raiford has served as our Vice President of Sales since January 2015. From 2012 to 2014, he served as our National Sales Director and has been responsible for building and leading the Sales Force since the inception of the Commercial Organization. In addition to the Sales Force, his ... responsibilities include Sales Operations, Sales Training, and Corporate Accounts. Prior to joining Supernus, Mr. Raiford held various positions at Shire Pharmaceuticals from 1995 to 2011, including Director-level positions in Sales, Sales Training/Leadership Development and Marketing. Mr. Raiford earned his B.A. in Communications,Public Relations from North Carolina State University. ...Read More +
Bryan A. Roecklein, Ph.D
SENIOR VICE PRESIDENT
Bryan A. Roecklein, Ph.D, joined in July 2015 as our Vice President of Corporate Development. Most recently he was a member of the U.S. Executive Team at Meda Pharmaceuticals, leading the Corporate Development function. Prior to that, he was Vice President of Marketing and Business ... Development, with responsibilities covering Marketing, Access, Trade and Acquisition Strategy. From 2001 to 2011, at MedPointe, then Meda Pharmaceuticals, Dr. Roecklein held various positions with increasing responsibility in Portfolio Management, New Product Planning, Marketing, Medical Education and Commercial Development. From 1998 to 2001, Dr. Roecklein led commercial development at Kimeragen and ValiGene, and from 1995-1998, he was an independent Investigator at the Fred Hutchinson Cancer Research Center.
Dr. Roecklein earned his B.S. from University of Maryland, College Park and Ph.D in Molecular, Cellular, and Developmental Biology from the University of Coloardo Boulder. ...Read More +
Jonathan Rubin, MD, MBA
SENIOR VICE PRESIDENT
CHIEF MEDICAL OFFICER
RESEARCH & DEVELOPMENT
Jonathan Rubin, MD, MBA has been the Chief Medical Officer and Senior Vice President of Research & Development at Supernus Pharmaceuticals, Inc. since January 1, 2021. Before joining the Company on February 10, 2020 as Senior Vice-President, Clinical Research and ... Medical Affairs, Dr. Rubin was Chief Medical Officer of Atentiv, Inc. from 2018 to 2020, where he was responsible for clinical strategy and the design of clinical trials. From 2017 to 2018, Dr. Rubin was a clinical consultant to Chondrial Therapeutics, Inc. responsible for developing clinical strategy and trials. From 2013 to 2017, Dr. Rubin was Chief Medical Officer of Alcobra, Inc., where he was responsible for oversight of the company’s clinical development, medical affairs, biometrics and pharmacovigilance departments, and he participated in the completion of two Phase III studies in ADHD and assisted with orphan drug and fast track designations for product candidates. From 2007 to 2013, Dr. Rubin was Medical Director of Clinical Development and Medical Affairs for Shire Pharmaceuticals, where he supported the company’s ADHD portfolio and assisted with the design, execution and interpretation of Phase II, Phase IIIB and Phase IV studies. Prior to entering the biopharmaceutical industry, Dr. Rubin was in private practice as a Developmental-Behavioral and General Pediatrician for 16 years. Dr. Rubin was a pediatric resident at Albert Einstein/Montefiore Hospital in the Bronx, New York and a fellow in ambulatory pediatrics at Boston’s Children Hospital. Dr. Rubin received his M.D. from the University of Connecticut School of Medicine, his Master of Business Administration from the Columbia School of Business and his Bachelor of Science in molecular biophysics and biochemistry from Yale University. ...Read More +
BOARD MEMBER PROFILES
Charles W. Newhall, III
Charles W. Newhall, III, has served as a member of our Board since 2005. In 1977, Mr. Newhall co-founded NEA, a venture capital firm that focuses on the medical and life sciences and information technology industries, from which he retired effective December 31, 2012. To date, Mr. Newhall has served ...as a director of over 50 venture-backed companies. Some of his current Board memberships include NeuroPace, Inc. and Interfusion. In 1986, he founded the Mid-Atlantic Venture Capital Association (MAVA), which now has a membership of 500 venture capital firms, and is one of the most active regional venture associations in the country. He is Chairman Emeritus of MAVA. He has served as an advisor to Greenspring Associates since 2012. Before NEA, Mr. Newhall was a Vice President of T. Rowe Price. He served in Vietnam commanding an independent platoon including an initial reconnaissance of Hamburger Hill. His decorations include the Silver Star, Bronze Star V (1st OLC), and the Purple Heart. He earned an Honors Degree in English from the University of Pennsylvania and an MBA from Harvard Business School. Mr. Newhall’s substantial experience with companies in the healthcare sector and his venture capital, financial, and business experience qualify him to serve as a director. ...Read More +
Carrolee Barlow, MD, Ph.D
Carolee Barlow, MD, Ph.D, was appointed to the Board of Directors in June 2018. Dr. Barlow is a renowned expert in neuroscience, neurodegeneration, and rare diseases, and is currently the Chief Medical Officer of ESCAPE Bio. ...
Dr. Barlow’s previous work spanned clinical care, laboratory and clinical research, academia, and industry. She is the former CEO of the Parkinson’s Institute and Clinical Center, an independent nonprofit organization providing research, clinical trials, and clinical care, as well as formed partnerships with biotech and pharmaceutical companies. Before joining the Parkinson’s Institute, Dr. Barlow was acting Chief Medical Officer at Amicus Therapeutics and also was a co-founder, Chief Scientific Officer, and Chief Medical Officer of BrainCells, Inc. Prior to BrainCells, she served as the Director of Molecular Neuroscience and Worldwide Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories, responsible for neuroscience biology, global exploratory, licensing and development efforts. She serves as an advisory board member and is on the Board of Directors of several biotechnology companies and disease foundations advancing therapies for rare diseases and disorders of the central nervous system. Dr. Barlow has held a faculty position at the Laboratory of Genetics at the Salk Institute for Biological Studies in La Jolla, California.
Dr. Barlow received her Bachelor of Arts in English from the University of Utah and Doctor of Medicine from the University of Utah School of Medicine. In addition, she received her Doctor of Philosophy in molecular and development biology from the Karolinska Medical Nobel Institute in Stockholm, Sweden. She is an author of approximately 100 peer-reviewed research papers, and book chapters, and is an inventor on numerous patents. ...Read More +
Georges Gemayel, Ph.D
George Gemayel, Ph.D, has served as a member of our Board since 2015. Since 2010, he has served as consultant for several biotechnology companies and venture capital funds. From February 2011 to December 2012, Dr. Gemayel served as Executive Chairman of Syndexa Pharmaceuticals ...Corp., a privately held drug development company. In 2010, Dr. Gemayel served as Executive Chairman of FoldRx until its acquisition by Pfizer. From June 2008 until November 2009, Dr. Gemayel served as President and CEO of Altus Pharmaceuticals, a publicly traded pharmaceutical company. In November 2009, while Dr. Gemayel was President, CEO, and a director, Altus Pharmaceuticals filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code and ceased operations at such time. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation, where he was responsible for Genzyme’s global therapeutics, transplant, renal and biosurgery business. From 2000 to 2003, Dr. Gemayel was employed as Vice President of National Specialty Care for Hoffmann La-Roche, responsible for its U.S. business for dermatology, oncology, transplantation, hepatitis, and HIV. Dr. Gemayel joined Hoffman La-Roche in 1988 and served in various positions of increasing responsibility over his tenure. Dr. Gemayel received his Doctorate in Pharmacy from Saint Joseph University in Beirut, Lebanon and his PhD in Pharmacology from Paris-Sud University in Paris, France. Dr. Gemayel currently serves as Chairman of the Board of Directors of Oxthera AB, Enterome Bioscience SA, and Orphazyme ApS, all privately held companies, as well as a Director of Raptor Pharmaceuticals, Dimension Therapeutics, and Momenta Pharmaceuticals (all NASDAQ-listed companies). He was previously a Director of Adcolor Corporation, a publicly traded company acquired by Cubis Pharmaceuticals, Inc., a Director at Prosena, acquired by Biomarin, a Director at NPS, acquired by Shire, a Director of EpiTherapeutics, acquired by Gilead, and the Chairman of Vascular Magnetics, a privately owned company. Dr. Gemayel’s substantial experience on the Board of Directors of life science and healthcare companies and his over 25 years of experience in the pharmaceutical industry, including management and executive positions spanning the United States, Europe, and the Middle East, qualify him to serve as a director. ...Read More +
Frederick M. Hudson
Frederick M. Hudson has served as a member of our Board since 2010. Mr. Hudson retired as a partner in the accounting firm of KPMG LLP in 2006 after a 37-year career with the firm. He was the partner in charge of the health care audit practice for the Washington-Baltimore business ...unit. He currently chairs the audit committee of the Board of Directors of Aradigm Corporation. He chairs the finance committee of the Board of Directors of GBMC Healthcare, Inc. and its affiliate, Greater Baltimore Medical Center, where he was the prior chair of the audit committee. He is also a director and compliance committee member of Maxim Healthcare Services. He was previously on the Board of Directors and was the audit committee chair of Educate, Inc., Woodhaven Holding Corp., Vicor Technologies, Inc., and Paradigm Management Services, LLC. He served on the Board of Financial Administration of the Catholic Archdiocese of Baltimore and on the Board of Trustees of the Maryland Historical Society. Mr. Hudson received a B.S. in Accounting from Loyola University Maryland and is a Certified Public Accountant. Mr. Hudson’s extensive accounting and health care audit experiences qualify him to serve as a director. ...Read More +
Jack A. Khattar
PRESIDENT AND CHIEF EXECUTIVE OFFICER, DIRECTOR
Jack A. Khattar is the founder of our Company and has served as our President, Chief Executive Officer, and Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions during that time as a Board member, President and CEO of Shire Laboratories Inc., the drug delivery subsidiary ...of Shire plc. From 1999 to 2004, he also served as a member of Shire plc’s Executive Committee. Prior to that, Mr. Khattar served as an Executive Officer and the Chairman of the Management Committee at CIMA Labs Inc. (CIMA), a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex and Kodak in various locations, including the United States, Europe and the Middle East. Mr. Khattar served on the Board of Rockville Economic Development, Inc. from 2003 to 2013. He currently serves on the Board of Directors of Prevacus, Inc., a privately-held development stage biotechnology company, and is also Chairman of the Board of scPharmaceuticals, a publicly traded biotechnology company. Mr. Khattar earned his degrees in Marking with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania. Mr. Khattar’s leadership, executive, managerial, business and pharmaceutical company experience, along with his more than 25 years of industry experience in the development and commercialization of pharmaceutical products and drug delivery technologies, qualify him to be a director. ...Read More +
John M. Siebert, Ph.D
John M. Siebert, Ph.D, has served as a member of our Board since 2011. Dr. Seibert has over 30 years’ experience in the pharmaceutical industry. Currently, Dr. Seibert is Founder and CEO of Compan Pharmaceuticals, a companion animal pharmaceutical company. From May 2014 to November ...2015, Dr. Seibert was CEO of Chase Pharmaceuticals, a company conducting clinical trials in Alzheimer’s Disease based on a unique hypothesis. From 2010 to 2014, he was a Parner and Chief Operating Officer of New Rhein Healthcare Investors, LLC, a private equity group. From 2008 to 2010, he was CEO and Founder of Company Pharmaceuticals. From May 2003 to October 2008, Dr. Seiberg was the Chairman and CEO of CyDex, Inc., a privately held specialty pharmaceutical company. From September 1995 to April 2003, he was President and CEO of CIMA, a publicly traded drug delivery company, and from July 1995 to September 1995, he was President and Chief Operating Officer of CIMA. From 1992 to 1995, Dr. Siebert was Vice President, Technical Affairs at Dey Laboratories, Inc., a privately held pharmaceutical company. From 1988 to 1992, he was head of Research and Development and Quality Control at a division of Bayer Corporation. Prior to that, Dr. Siebert was employed by E.R. Squibb & Sons, Inc., G.D. Searle & Co., Gillette, and The Procter & Gamble Company. Dr. Seibert holds a B.S. in Chemistry from Illinois Benedictine University, an M.S. in Organic Chemistry from Wichita State University, and a PhD in Organic Chemistry from the University of Missouri. Dr. Seibert also serves on two other boards, Accubreak Pharmaceuticals and Aradigm Corporation, where he is the Chairman of the Compensation Committee and a member of the Audit Committee and the Nominating and Governance Committee. Dr. Seibert’s substantial operational and business experience with companies in the healthcare sector, combined with his scientific experience, qualify him to serve as a director. ...Read More +